Sodium Aurothiomalate (Gold)
Brand names: Myocrisin
Sodium aurothiomalate is an injectable gold compound used as a disease-modifying antirheumatic drug in rheumatoid arthritis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Gold is taken up by synovial macrophages and modulates immune and inflammatory responses, although the exact mechanism reducing joint inflammation is incompletely understood.
Prescribing in practice
- It can cause serious bone marrow suppression and nephrotoxicity, so blood counts and urinalysis must be checked before each dose and treatment withheld if abnormalities arise.
- Given by deep intramuscular injection, typically with a small test dose before the first full dose.
- It is now seldom used, having been superseded by methotrexate and biologic therapies.
Monitoring
Check full blood count and urine for protein before every injection, as recommended in current prescribing references, and review the skin and mucous membranes for reactions.
Counselling the patient
- Report any rash, mouth ulcers, sore throat, bruising or bleeding without delay.
- Attend for the required blood and urine tests before each injection.
Evidence & guidelines
Injectable gold is a long-established disease-modifying agent but is now rarely used owing to toxicity and the availability of more effective alternatives.
Reference: BSR/BHPR RA Guidelines; SPC Myocrisin; DMARD Prescribing Guidelines (NHSE); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- MELD-Na Score · Liver Disease
- Rome IV Diagnostic Criteria for Globus · Functional GI Disorders
- MELD-Na Score for Liver Cirrhosis · Hepatology
- Prognostic Indicator Guidance (PIG) / Gold Standards Framework · Prognosis
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022